Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 73 articles:
HTML format



Single Articles


    July 2021
  1. DI VINCENZO A, Andrisani A, Vettor R, Rossato M, et al
    Estrogen and COVID-19: friend or foe?
    Ann Oncol. 2021;32:933-934.
    PubMed    


    June 2021
  2. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02020.
    PubMed    


    March 2021
  3. BAERT T, Ferrero A, Sehouli J, O Donnell DM, et al
    The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    Ann Oncol. 2021 Mar 3. pii: S0923-7534(21)00155.
    PubMed     Abstract available


  4. MOORE KN, Oza AM, Colombo N, Oaknin A, et al
    Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Ann Oncol. 2021 Mar 2. pii: S0923-7534(21)00157.
    PubMed     Abstract available


    January 2021
  5. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
    PubMed    


  6. WU XH, Zhu JQ, Yin RT, Yang JX, et al
    Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    Ann Oncol. 2021 Jan 13. pii: S0923-7534(21)00008.
    PubMed     Abstract available


  7. TOBALINA L, Armenia J, Irving E, O'Connor MJ, et al
    A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Ann Oncol. 2021;32:103-112.
    PubMed     Abstract available


    December 2020
  8. PILIE PG, George A, Yap TA
    Patient selection biomarker strategies for PARP inhibitor therapy.
    Ann Oncol. 2020;31:1603-1605.
    PubMed    


    September 2020
  9. MILLER RE, Leary A, Scott CL, Serra V, et al
    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
    PubMed     Abstract available


    June 2020
  10. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    The forefront of ovarian cancer therapy: update on PARP inhibitors.
    Ann Oncol. 2020 Jun 19. pii: S0923-7534(20)39891.
    PubMed     Abstract available


    May 2020
  11. MILLSTEIN J, Budden T, Goode EL, Anglesio MS, et al
    Prognostic gene expression signature for high-grade serous ovarian cancer.
    Ann Oncol. 2020 May 27. pii: S0923-7534(20)39841.
    PubMed     Abstract available


    February 2020
  12. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed     Abstract available


    July 2019
  13. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
    Ann Oncol. 2019;30:1080-1087.
    PubMed     Abstract available


  14. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019;30:1025-1028.
    PubMed    


    May 2019
  15. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019 May 21. pii: 5492551. doi: 10.1093.
    PubMed    


  16. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
    Ann Oncol. 2019 May 2. pii: 5482567. doi: 10.1093.
    PubMed     Abstract available


  17. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger.
    Ann Oncol. 2019 May 2. pii: 5482247. doi: 10.1093.
    PubMed     Abstract available


  18. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
    Ann Oncol. 2019;30:845-852.
    PubMed     Abstract available


  19. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
    Ann Oncol. 2019;30:721-732.
    PubMed     Abstract available


  20. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
    Ann Oncol. 2019;30:672-705.
    PubMed     Abstract available


    April 2019
  21. LORUSSO D, Pignata S, Gonzalez-Martin A
    Chemotherapy-free treatments: are we ready for prime time?
    Ann Oncol. 2019;30:497-498.
    PubMed    


  22. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019;30:551-557.
    PubMed     Abstract available


    March 2019
  23. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of Patients with Recurrent Epithelial Ovarian Cancer for Whom Platinum is Still an Option.
    Ann Oncol. 2019 Mar 18. pii: 5384492. doi: 10.1093.
    PubMed     Abstract available


  24. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study.
    Ann Oncol. 2019 Mar 9. pii: 5372686. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  25. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019 Feb 7. pii: 5308594. doi: 10.1093.
    PubMed     Abstract available


  26. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    24PReactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30.
    PubMed    


  27. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2019;30:303-309.
    PubMed     Abstract available


  28. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30 Suppl 1:i8-i9.
    PubMed    


  29. STONE A, Gebski V, Davidson R, Bloomfield R, et al
    Exaggeration of PFS by blinded, independent, central review (BICR).
    Ann Oncol. 2019;30:332-338.
    PubMed     Abstract available


    December 2018
  30. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2018 Dec 21. pii: 5255827. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  31. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  32. FOTOPOULOU C, Sehouli J, Mahner S, Harter P, et al
    HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
    Ann Oncol. 2018 Jun 4. pii: 5032848. doi: 10.1093.
    PubMed    


    May 2018
  33. MIRZA MR, Pignata S, Ledermann JA
    Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Ann Oncol. 2018 May 10. pii: 4994787. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  34. RAY-COQUARD I, Morice P, Lorusso D, Prat J, et al
    Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 Apr 25. pii: 4983953. doi: 10.1093.
    PubMed    


    February 2018
  35. PICCIRILLO MC, Scambia G, Bologna A, Signoriello S, et al
    Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2018 Feb 16. pii: 4864364. doi: 10.1093.
    PubMed     Abstract available


  36. BIRKBAK NJ, Li Y, Pathania S, Greene-Colozzi A, et al
    Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
    Ann Oncol. 2018 Feb 14. pii: 4857262. doi: 10.1093.
    PubMed     Abstract available


  37. OSKAY-OZCELIK G, Alavi S, Richter R, Keller M, et al
    EXPRESSION III: Patient s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.
    Ann Oncol. 2018 Feb 5. pii: 4838337. doi: 10.1093.
    PubMed     Abstract available


  38. BANERJEE S, Oza AM, Birrer MJ, Hamilton EP, et al
    Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Ann Oncol. 2018 Feb 1. pii: 4833235. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  39. FRIEDLANDER M, Rau J, Lee CK, Meier W, et al
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenan
    Ann Oncol. 2017 Dec 18. pii: 4756055. doi: 10.1093.
    PubMed     Abstract available


    November 2017
  40. PROVENCHER DM, Gallagher CJ, Parulekar WR, Ledermann JA, et al
    OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
    Ann Oncol. 2017 Nov 23. pii: 4654091. doi: 10.1093.
    PubMed     Abstract available


  41. LEDERMANN JA
    Front-line therapy of advanced ovarian cancer: new approaches.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  42. MONK BJ, Chan JK
    Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  43. MARTH C, Reimer D, Zeimet AG
    Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  44. BOOKMAN MA, Okamoto A, Stuart G, Yanaihara N, et al
    Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  45. BRAND AH, DiSilvestro PA, Sehouli J, Berek JS, et al
    Cytoreductive surgery for ovarian cancer: quality assessment.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  46. CHRISTIE EL, Bowtell DDL
    Acquired chemotherapy resistance in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  47. ODUNSI K
    Immunotherapy in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  48. EISENHAUER EA
    Real-world evidence in the treatment of ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  49. PUJADE-LAURAINE E
    New treatments in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  50. PIGNATA S, C Cecere S, Du Bois A, Harter P, et al
    Treatment of recurrent ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


  51. PARK SB, Kwok JB, Asher R, Lee CK, et al
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Ann Oncol. 2017;28:2733-2740.
    PubMed     Abstract available


  52. DUSKA LR, Kohn EC
    The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
    Ann Oncol. 2017;28.
    PubMed     Abstract available


    September 2017
  53. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed    


  54. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Abstract available


    June 2017
  55. RONCOLATO FT, Gibbs E, Lee CK, Asher R, et al
    Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.
    Ann Oncol. 2017 Jun 8. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  56. CONDORELLI R, Andre F
    Combining PI3K and PARP inhibitors for breast and ovarian cancer tratement.
    Ann Oncol. 2017 May 15. doi: 10.1093.
    PubMed    


  57. BAMIAS A, Gibbs E, Khoon Lee C, Davies L, et al
    Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
    Ann Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Abstract available


  58. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017;28:996-1004.
    PubMed     Abstract available


    April 2017
  59. CHIANNILKULCHAI N, Pautier P, Genestie C, Bats AS, et al
    Networking for ovarian rare tumors: a significant breakthrough improving disease management.
    Ann Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Abstract available


  60. RAY-COQUARD I, Lorusso D
    Immunotherapy and Epithelial Ovarian Cancer: a double-edged sword?
    Ann Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed    


    March 2017
  61. POVEDA A, Del Campo JM, Ray-Coquard I, Alexandre J, et al
    Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Abstract available


    February 2017
  62. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Abstract available


  63. KARAM A, Ledermann JA, Kim JW, Sehouli J, et al
    Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Abstract available


    January 2017
  64. MCGEE J, Bookman M, Harter P, Marth C, et al
    5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors.
    Ann Oncol. 2017 Jan 24. pii: mdx010. doi: 10.1093.
    PubMed     Abstract available


    December 2016
  65. WILSON MK, Pujade-Lauraine E, Aoki D, Mirza MR, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease.
    Ann Oncol. 2016.
    PubMed     Abstract available


  66. LEARY AF, Quinn M, Fujiwara K, Coleman RL, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): Clinical trial design for rare ovarian tumours.
    Ann Oncol. 2016.
    PubMed     Abstract available


  67. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Abstract available


    November 2016
  68. MESNAGE SJ, Auguste A, Genestie C, Dunant A, et al
    Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Ann Oncol. 2016.
    PubMed     Abstract available


  69. LIU JF, Moore KN, Birrer MJ, Berlin S, et al
    Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Ann Oncol. 2016;27:2124-2130.
    PubMed     Abstract available


  70. WEIDERPASS E, Botteri E
    Ovarian cancer mortality trends: which factors are involved?
    Ann Oncol. 2016;27:1977-1978.
    PubMed    


  71. MANGILI G, Sigismondi C, Lorusso D, Cormio G, et al
    The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
    Ann Oncol. 2016.
    PubMed     Abstract available


    September 2016
  72. LEDERMANN JA, Sessa C, Colombo N
    appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies).
    Ann Oncol. 2016;27.
    PubMed    


  73. PALUCH-SHIMON S, Cardoso F, Sessa C, Balmana J, et al
    Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
    Ann Oncol. 2016;27.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: